Immunovant

(NASDAQ) IMVT

Current Price$27.74

Market Cap$5.52B

Since IPO (2019)+173%

5 Year+73%

1 Year+71%

1 Month+8%

Immunovant Financials at a Glance

Market Cap

$5.52B

Revenue (TTM)

$0.00

Net Income (TTM)

$464.20M

EPS (TTM)

$-2.68

P/E Ratio

-10.11

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$27.74

Volume

41,586

Open

$26.96

Price

$27.74

Volume

41,586

Open

$26.96

Previous Close

$27.12

Daily Range

$26.86 - $27.77

52-Week Range

$13.36 - $30.09

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$27.74

Volume

41,586

Open

$26.96

Previous Close

$27.12

Daily Range

$26.86 - $27.77

52-Week Range

$13.36 - $30.09

IMVT News

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

Seena HassounaMar 15, 2026

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish

Jonathan PoncianoMar 11, 2026

Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million?

Robert IzquierdoDec 18, 2025

Two people in white lab coats looking at a computer display

Page 1

IMVT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immunovant

Industry

Biotechnology

Sector

Health Care

Employees

362

CEO

Eric Venker, MD, PharmD

Website

www.immunovant.com

Headquarters

New York City, NY 10018, US

IMVT Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-69%

Return on Capital

-49%

Return on Assets

-44%

Earnings Yield

-9.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.52B

Shares Outstanding

203.53M

Volume

41.59K

Avg. Volume

1.43M

Financials (TTM)

Gross Profit

$0.00

Operating Income

$438.15M

EBITDA

$437.77M

Operating Cash Flow

$375.87M

Capital Expenditure

$759.00K

Free Cash Flow

$376.63M

Cash & ST Invst.

$713.97M

Total Debt

$98.00K

Immunovant Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$101.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.52B

N/A

Market Cap/Employee

$15.25M

N/A

Employees

362

N/A

Net Income

$110.64M

+0.4%

EBITDA

$108.98M

+4.6%

Quarterly Fundamentals

Name

Q3 2026YOY CHG

Net Cash

$994.52M

+165.4%

Accounts Receivable

$1.64M

-26.1%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-44.11%

N/A

Return on Invested Capital

-49.40%

N/A

Free Cash Flow

$92.33M

+8.2%

Operating Cash Flow

$92.33M

+8.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AKROAkero Therapeutics, Inc.

AKROAkero Therapeutics, Inc.$54.65+0.00%

CRNXCrinetics Pharmaceuticals, Inc.

CRNXCrinetics Pharmaceuticals, Inc.$41.20+5.59%

KYMRKymera Therapeutics, Inc.

KYMRKymera Therapeutics, Inc.$84.01+4.09%

PRAXPraxis Precision Medicines, Inc.

PRAXPraxis Precision Medicines, Inc.$337.24+4.02%

ACADACADIA Pharmaceuticals Inc.

ACADACADIA Pharmaceuticals Inc.$22.18+1.03%

VKTXViking Therapeutics, Inc.

VKTXViking Therapeutics, Inc.$31.94+6.47%

NAMSNewAmsterdam Pharma Company N.V.

NAMSNewAmsterdam Pharma Company N.V.$29.77+4.71%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

CNSPCns Pharmaceuticals

CNSPCns Pharmaceuticals$7.71+2.33%

GBTGGlobal Business Travel Group

GBTGGlobal Business Travel Group$9.34+0.57%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.21+0.01%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.69-0.00%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$45.30+0.02%

BBBlackBerry

BBBlackBerry$5.62+0.04%

NCLHNorwegian Cruise Line

NCLHNorwegian Cruise Line$17.13-0.09%

Questions About IMVT

What is the current price of Immunovant?

Immunovant is trading at $27.74 per share.

What is the 52-week range for Immunovant?

Over the past 52 weeks, Immunovant has traded between $13.36 and $30.09.

How much debt does Immunovant have?

As of the most recent reporting period, Immunovant reported total debt of N/A.

How much cash does Immunovant have on hand?

Immunovant reported $994.52M in cash and cash equivalents in its most recent financial results.

What is Immunovant’s dividend yield?

Immunovant does not currently have a dividend yield.

Immunovant

Immunovant Financials at a Glance

IMVT News

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish

Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million?

Why Immunovant Stock Blasted Higher Today

Immunovant Posts 34% R&D Jump in Q1

Why Immunovant Stock Is Bolting Higher Today

Why Shares of Immunovant Are Soaring on Tuesday

These 2 Biotech Stocks Are Bucking a Down Market Tuesday

IMVT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Immunovant

IMVT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Immunovant Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IMVT

What is the current price of Immunovant?

What is the 52-week range for Immunovant?

How much debt does Immunovant have?

How much cash does Immunovant have on hand?

What is Immunovant’s dividend yield?

Premium Investing Services